CalmiGo

Elysium publishes positive results from two studies for Basis

Latest articles

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Product review: Bearaby weighted blanket

Bearaby weighted blankets are on a mission to provide you with deep sleep, peace of mind and a joyful feeling.   GO LONG    GO SHORT ...

Aging well: the new human imperative

Prof Andrew Scott touts the importance of compressing morbidity and aging well to realise multi-trillion dollar benefit of increasing life expectancy. Earlier this year, we...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
Seno

Editor's picks

Billionaire donates $220m for peak performance research

Salk Institute, UC San Diego and Stanford given $220 million by Wu Tsai Human Performance Alliance to research molecular underpinnings of peak human performance. A Salk...

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Product review: Bearaby weighted blanket

Bearaby weighted blankets are on a mission to provide you with deep sleep, peace of mind and a joyful feeling.   GO LONG    GO SHORT ...
CalmiGo

Click the globe for translations.

Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction.

In December 2019, Elysium announced a $40m Series C round, followed by the January 2020 announcement of a clinical trial to study correlations between epigenetic aging and NAD+ levels in our bodies.

Longevity.Technology: The Longevity supplements market is heating up, and the release of trial data from New York-headquartered Elysium Health demonstrates that momentum of the Longevity supplements market is set for growth.

Due to the ongoing coronavirus pandemic, Elysium’s NAD+ baseline study is ongoing, but the company recently shared the results of two studies for Basis with Longevity.Technology.

The first, an acute kidney injury (AKI) Phase I dose-escalating safety study conducted at Massachusetts General Hospital, enabled the company to receive acceptance of its first Investigational New Drug (IND) application from the FDA late last year. A rare achievement for a dietary supplement, the IND approval allows for a Phase II AKI clinical trial to evaluate the efficacy of Basis for kidney protection against AKI in surgical cardiac patients, which is scheduled to begin later this year.

The second published study – a 90-day toxicity study – demonstrates the superior safety of Elysium’s proprietary nicotinamide riboside (NR-E) compared to other NAD+ precursor consumer products. The studies mark the third and fourth publications for Elysium, following the publication of the company’s first clinical trial in 2017, which demonstrated that Basis safely and sustainably increases NAD+ levels by an average of 40%, and the publication of a pilot study evaluating the efficacy of the company’s experimental therapeutic EH301 for amyotrophic lateral sclerosis (ALS). The news of the two studies is encouraging and comes on the back of the launch of Elysium’s long-term brain health product ‘Matter’, which was developed in partnership with the University of Oxford.

 


 

“… IND approval is an exciting advancement for Elysium Health but also more broadly for the field of aging research, as it allows for the further exploration of a potential treatment that targets a fundamental process of aging.”

 


 

Commenting on the AKI Phase I trial, Leonard Guarente, Ph.D., Elysium chief scientist and director of the Glenn Center for Biology of Aging Research at MIT said: “Our Phase I trial was a collaboration that was made possible by Elysium’s open-access research model, and it combined research that has come out of numerous labs with ongoing work related to AKI and chronic kidney disease at Massachusetts General Hospital. The IND approval is an exciting advancement for Elysium Health but also more broadly for the field of aging research, as it allows for the further exploration of a potential treatment that targets a fundamental process of aging.”

Nicotinamide riboside is a precursor to NAD+ and classifies as GRAS (generally recognized as safe) for use in foods. While it may be true that the NAD+ synthesis enzyme, NAMPT, declines with aging, it is only one contributing factor to the age-related reduction in NAD+.

New market-entrant Nuchido, whose CEO we interviewed last week, claims that its NAD+ supplement can increase NAD+ levels by a factor of four, but we understand that they have not yet demonstrated such an increase in a placebo-controlled clinical trial and it is perhaps unnecessary according to Guarente.

Guarente added: “In 2016, Elysium Health demonstrated in a 120-person, eight-week, placebo-controlled, double-blinded, randomized trial that the recommended dose of Basis safely and sustainably increases NAD+ levels by an average of 40%. NAD+ only declines by less than twofold with aging, so any increase beyond twofold may be unimportant. Unlike other NAD+ boosting products, Basis contains not only an NAD+ precursor, nicotinamide riboside, but also pterostilbene, which activates the critical sirtuin, SIRT1, selectively and allows synergy with NAD+ boosters. “Data with an N=1 presented in a recent poster from Nuchido can not be taken as a reliable indication of the effects of an intervention on raising NAD+ levels.”

‘Basis’ is available from Elysium with prepaid subscription plans starting at $40 per month; single bottles are also offered for purchase.

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
CalmiGo

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Seno

Related articles

Longevity senotherapeutics report: Insilico Medicine

Insilico – on a mission to accelerate senescence drug discovery and development by continuously inventing and deploying new AI technologies. Over the coming weeks, we...

Targeting senescence improves kidney regenerative functions

A new study finds that the administration of a compound selectively toxic to senescent cells, can improve functional renal recovery, reduce fibrosis and increase...

US Special Ops will test antiaging pill

From delaying the onset of aging, to improving recovery time, the US military has its sights set on the age of marvel. From duct tape...

Longevity senotherapeutics report: Cleara Biotech

Cleara Biotech – on a mission to target cellular senescence to extend human healthspan at old age. Over the coming weeks, we will be bringing...

Campisi Lab to partner with pharma firm on senescence

Buck professor talks about taking the right approach to senescence, key indications, and forthcoming research and collaborations from her lab. In our first article with...
Seno